Bank of India Flexi Cap Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity-related securities across various market capitalisation.
Growthvine rating: 5/5 — ranked #3 of 56 in category.
Fund basics
| Category | Equity: Flexi Cap |
|---|
| NAV | ₹39.27 (as of 2026-11-13) |
|---|
| AUM | ₹3,137 Cr |
|---|
| Expense ratio | 1.66% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Alok Singh |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 13.24% |
|---|
| Sharpe ratio | 0.61 |
|---|
| Standard deviation | 18.80% |
|---|
| Max drawdown | −23.98% |
|---|
| Alpha | 5.87 |
|---|
| Beta | 1.08 |
|---|
Over 5 years, captured 120.7% of Nifty 500's upside and 106.4% of its downside.
Market cap allocation
| Large cap | 44.8% |
|---|
| Mid cap | 19.8% |
|---|
| Small cap | 35.5% |
|---|
Concentration
| Top 5 holdings | 18.5% |
|---|
| Top 10 holdings | 31.4% |
|---|
| Total holdings | 62 |
|---|
| Index overlap | 24.9% |
|---|
| Active share | 75.1% |
|---|
Top holdings
- State Bank Of India — 5.6%
- ICICI Bank Ltd. — 4.5%
- TREPS — 3.3%
- Hindustan Aeronautics Limited — 2.8%
- Sky Gold And Diamonds Limited — 2.8%
- Dr. Reddys Laboratories Ltd. — 2.7%
- Adani Ports and Special Economic Zone Ltd — 2.7%
- Mankind Pharma Limited — 2.6%
- Larsen & Toubro Limited — 2.6%
- Indian Bank — 2.5%
Top sectors
- Banking & Financial — 18.8%
- Pharma & Biotech — 7.9%
- Energy — 7.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 11.2% | Q1 (Top) | #4 of 50 |
| 2025 | −0.3% | Q4 (Bottom) | #35 of 43 |
| 2024 | 29.0% | Q1 (Top) | #4 of 42 |
| 2023 | 37.9% | Q1 (Top) | #2 of 36 |
| 2022 | −0.9% | Q3 | #17 of 30 |